Table 4 Description of the study cohort living in the CMA of Montreal (n = 111,556): outcomes and health care utilizations by immigration quintiles
| Â | Â | Â | Â | Immigration | Â | Â | Trend test ** |
|---|---|---|---|---|---|---|---|
Dependent variables | TOTAL | Q1 - Low | Q2 | Q3 | Q4 | Q5 - High | β (p - value) |
TOTAL study cohort, n (%) | 111,556 (100) | 19,833 (17.8) | 20,838 (18.7) | 22,240 (19.9) | 23,318 (20.9) | 25,327 (22.7) | − |
All-cause death, n (%) | 6,453 (5.8) | 1,172 (5.9) | 1,205 (5.8) | 1,364 (6.1) | 1,352 (5.8) | 1,360 (5.4) | −0.021 (0.0203) |
All-cause hospitalization, n (%) | 35,928 (32.2) | 6,370 (32.1) | 6,711 (32.2) | 7,304 (32.8) | 7,605 (32.6) | 7,938 (31.3) | −0.006 (0.1635) |
CVD event, n (%) | 6,064 (5.4) | 1,109 (5.6) | 1,216 (5.8) | 1,201 (5.4) | 1,299 (5,6) | 1,239 (4.9) | −0.034 (0.0003) |
ED frequent users (≥4), n (%) | 29,247 (26.2) | 4,617 (23.3) | 5,049 (24.2) | 5,844 (26.6) | 6,443 (27.6) | 7,294 (28.8) | 0.075 (<.0001) |
GP frequent users (≥20), n (%) | 29,568 (26.5) | 5,669 (28.6) | 5,572 (26.7) | 5,894 (26.5) | 6,139 (26.3) | 6,294 (24.8) | −0.040 (<.0001) |
MD specialists frequent users (≥5), n (%) | 29,975 (26.9) | 4,238 (21.4) | 5,306 (25.5) | 6,333 (28.5) | 6,771 (29.0) | 7,327 (28.9) | 0.092 (<.0001) |
Sub-cohort admissible to public drug plan, n (%) | 71,620 (100) | 11,169 (15.6) | 12,058 (16.8) | 13,894 (19.4) | 15,669 (21.9) | 18,830 (26.3) | − |
Antidiabetic drugs, n (%) | 61,395 (85.7) | 9,462 (84.7) | 10,247 (85.0) | 11,749 (84.6) | 13,429 (85.7) | 16,508 (87.7) | 0.059 (<.0001) |